Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.
The post discusses hair growth progress and treatments used, including finasteride, minoxidil, and various hair care products like Australian organic argan oil mask and products from dslaboratories. The user is considering switching to a finasteride and minoxidil pill combination and testing a grayhair serum.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in grayhair.
A user is organizing a group buy for various compounds aimed at reversing hair loss and grayhair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
The user began using topical minoxidil in 2020 without regrowth, then added 0.5mg finasteride, 2.5mg oral minoxidil daily, topical minoxidil/finasteride most days, and weekly micro needling since December 2022. They also use peppermint-infused jojoba oil for hair health and have noticed less grayhair.
A user noticed that after using finasteride and a regrowth spray, their new hair strands are all black, unlike their previously white hair. They are puzzled by this change and seek an explanation.
The user is treating hair loss with topical Minoxidil, Finasteride, RU58841, microneedling, and Ketoconazole. For grey hair, they use L-Cysteine, L-Methionine, and PABA, and have noticed some re-pigmentation.
Zinc supplements can make existing hair thicker and fuller but do not cure or slow hair loss. Long-term zinc use requires copper supplementation to avoid deficiencies.
The conversation is about the impressive hair density and hairline of a person, with users attributing it to good genetics and joking about the lack of hair loss despite stress. Specific hair loss treatments like Minoxidil, Finasteride, or RU58841 are not discussed.
The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
A 30-year-old man using minoxidil for hair loss is seeing stabilization but no significant regrowth. He is hesitant about finasteride due to potential side effects and is seeking alternative methods to promote hair growth.
The post discusses the theory that melatonin could reverse grey hair by regulating certain enzymes. However, users who have taken melatonin reported no effect on preventing or reversing grey hair.
A user reports positive results after 6 months using a topical finasteride/minoxidil spray and a hair and nail health vitamin for hair loss. They were initially skeptical but now are satisfied with their hair appearing to age gracefully.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The conversation discusses hair regrowth progress after 2.5 months using pyrilutamide and minoxidil. Participants note visible improvement in a short time.
The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.
The post discusses hair regrowth progress after 3 months of using Minoxidil four times a week, dermarolling twice a week, and using an anti-gray shampoo. The conversation includes speculation about the effectiveness of the shampoo, with some users noting visible darkening and growth of hair.
The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.
The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.
A hair transplant experience after 6 months, with 4100 grafts, which took 3 months to stop looking obvious and included finasteride treatment. It also discusses the differences between DHI and FUE methods.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.